Drumakers likely to face tough times in second half

Published: 2013-07-09 07:00:00

Updated: 2013-07-09 07:00:00

The prevailing view in the pharmaceutical industry is that the tough times will continue in the second half of this year because there is no immediate sign of a drug demand rebound.

Korean drugmakers are fighting an uphill battle on multiple fronts that is increasingly denting their bottom li...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK